Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Cboe UK SEK

AstraZeneca PLC (AZNS.XC)

Compare
1,464.50
+4.50
+(0.31%)
At close: April 3 at 12:42:27 PM GMT+1
Loading Chart for AZNS.XC
  • Previous Close 1,460.00
  • Open 1,464.50
  • Bid 1,448.50 x --
  • Ask 1,443.50 x --
  • Day's Range 1,464.50 - 1,464.50
  • 52 Week Range 1,383.50 - 1,790.75
  • Volume 6
  • Avg. Volume 78
  • Market Cap (intraday) --
  • Beta (5Y Monthly) 0.25
  • PE Ratio (TTM) --
  • EPS (TTM) --
  • Earnings Date Apr 29, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, Byetta, XIGDUO, Accolate, Accoleit, Vanticon, Beyfortus, Synagis, FluMist, tixagevimab and cilgavimab, and sipavibart. It also provides Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Bricanyl Turbuhaler, Rhinocort, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Breztri Aerosphere, Duaklir Genuair, Kavigale, Evusheld, Fluenz/FluMist, and Voydeya. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the United States, Europe, and Asia. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

www.astrazeneca.com

94,300

Full Time Employees

December 31

Fiscal Year Ends

--

Sector

--

Industry

Recent News: AZNS.XC

View More

Performance Overview: AZNS.XC

Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .

YTD Return

AZNS.XC
0.00%
MSCI WORLD (^990100-USD-STRD)
5.04%

1-Year Return

AZNS.XC
0.00%
MSCI WORLD (^990100-USD-STRD)
3.97%

3-Year Return

AZNS.XC
4.31%
MSCI WORLD (^990100-USD-STRD)
14.26%

5-Year Return

AZNS.XC
4.31%
MSCI WORLD (^990100-USD-STRD)
98.14%

Compare To: AZNS.XC

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: AZNS.XC

View More

Valuation Measures

Annual
As of
  • Market Cap

    --

  • Enterprise Value

    --

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    13.01%

  • Return on Assets (ttm)

    7.88%

  • Return on Equity (ttm)

    17.59%

  • Revenue (ttm)

    54.07B

  • Net Income Avi to Common (ttm)

    7.03B

  • Diluted EPS (ttm)

    --

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    5.53B

  • Total Debt/Equity (mrq)

    74.53%

  • Levered Free Cash Flow (ttm)

    8.46B

Research Analysis: AZNS.XC

View More

Company Insights: AZNS.XC

Research Reports: AZNS.XC

View More